Top Biotechnology Startups in 2027

We push the boundaries of molecular diagnostics through quantitative technologies. BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending QCT molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.

Ataraxis AI is a VC-backed start-up working at the intersection of multi-modal AI, oncology, and precision medicine. We are building cutting-edge diagnostic tools to assist physicians in selecting the most optimal treatments for their patients. We are a team of AI researchers, medical doctors and operators advised by a team of advisors who are pioneers in their respective fields, including the AI godfather, Yann LeCun, and oncologists at top cancer research institutes. At Ataraxis, you will have a unique opportunity to shape not just the future of our company, but the future of healthcare. We are looking to bring on highly motivated candidates to fulfill this mission.

Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world's medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Our dedication to our mission is fueling explosive growth, with both our test volume and revenue doubling year-over-year for the past four years. Our team has grown from 300 employees to more than 1,000 in just two years and we have helped hundreds of thousands of patients get the answers they need. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the exploding medical genetics industry by harnessing the power of advanced technologies – robotics, artificial intelligence, machine learning, software engineering – and world-class genetic expertise. We provide genetic information that guides decisions for patients facing a vast array of health questions, from ultra-rare diseases and the most common cancers to starting a family. The team driving our mission thrives in a culture designed to enable innovation at scale. We are grounded in freedom with responsibility and a universal sense of urgency and ownership. Employees are empowered to speak up, try new things and make decisions that push us forward. We provide all employees with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. Each day at Invitae means driving forward toward a new era in which everyone can have their health decisions guided by genetics.

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. If you crave challenges, understudied problems, and the chance to see your work impact the millions of lives touched by cancer, there’s no better place to be. We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential. By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.

Volta Labs was spun out of MIT in 2018 with the simple mission of building biological automation from the ground up. Volta is in the proximity of Kendall Square, known as "the most innovative square mile on the planet". Being part of the open biotech culture in Kendall Square made us realize that today’s biologists are held back by the limitations of existing automation tools. With DNA sequencing in particular, we observed that the advances in DNA readout technologies had moved further along than the advances in the upstream steps of preparing samples for sequencing (sample prep). ‍ What started out as a simple printed circuit board to manipulate colored droplets at the MIT Media Lab during co-founder Udayan Umapathi’s graduate work was quickly directed toward solving the “sample prep bottleneck”. The company raised Seed Funding from top VCs in 2019 and later that year added Will Langford as a co-founder and Head of Engineering. ‍ Since then, we have been heads down in the lab inventing and building novel fluidic and sample manipulation technologies. We take an anti-disciplinary approach to solve very hard problems and weave together instrumentation, fluidics, software, biology and chemistry. While our current focus is on sequencing sample prep, we envision a new approach where a single universal machine automates most biological workflows in genomics, proteomics and synthetic biology.

Founded by a biologist and an architect, our team has exemplified the power of interdisciplinary collaboration from its beginning. We believe that sewage offers a unique opportunity to make public health more data-driven and effective and that the best technologists can improve society, not just your photo filters. We believe that building cutting-edge technology that positively impacts our world requires collaboration across many disciplines with people from all walks of life. We equally value the perspective of technical experts and community stakeholders. We believe in radical transparency both internally and with our customers. We commit to creating a data ecosystem that respects the privacy of individuals and communities.

Stealth

Imaging trying to write software on an OS that changes every day - that's what life science is like. Only about 20% of published research is fully reproducible, and we think that needs to change dramatically. Drug development shouldn't take decades and billions of dollars - we need to become better at creating new medicines faster and more cheaply. All of that starts with trusting your experimental data. Our mission is to accelerate the pace of scientific discovery by collecting data from the real world (ie the "physical OS") to tackle the reproducibility problem. We do this by building sensors and using machine learning to help scientists understand their own data better so they can work faster and more reliably.

Seed Health, Inc. is a microbial sciences company pioneering applications of bacteria to impact human and environmental health. In collaboration with leading academic partners, our foundry model accelerates breakthrough science to develop live biotherapeutics and consumer innovations. Our Scientific Advisory Board is comprised of leading scientists with expertise in microbiology, immunology, genetics, metabolomics, gastroenterology, pediatrics, environmental sciences, and women’s health. Learn more—seedhealth.com Our consumer portfolio, Seed®, develops next-generation probiotics for specific developmental stages and various ecosystems of the body—seed.com

James Lind pioneered the first clinical trial in the 18th century, using oranges and lemons as a cure for scurvy. Like Lind, our mission is to improve health outcomes for all. Today clinical trials are slow, inefficient and hugely expensive. The result is that patients lose out on new treatments. Lindus Health will fix this. We're building the platform for the next generation of clinical trials.